iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) Receiving Somewhat Positive Press Coverage, Analysis Shows

News articles about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the financial services provider an impact score of 45.6776077252418 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

A number of equities analysts have recently weighed in on IBB shares. Vetr raised iShares Nasdaq Biotechnology Index Fund from a “hold” rating to a “buy” rating and set a $300.66 price objective for the company in a research note on Tuesday, April 18th. Credit Suisse Group raised iShares Nasdaq Biotechnology Index Fund from a “market weight” rating to an “overweight” rating in a research note on Tuesday, March 21st. They noted that the move was a valuation call.

iShares Nasdaq Biotechnology Index Fund (IBB) opened at 315.08 on Tuesday. iShares Nasdaq Biotechnology Index Fund has a 1-year low of $246.71 and a 1-year high of $323.45. The stock has a 50 day moving average price of $297.52 and a 200-day moving average price of $288.98.

The business also recently declared a quarterly dividend, which was paid on Friday, June 30th. Shareholders of record on Thursday, June 29th were given a dividend of $0.1768 per share. The ex-dividend date was Tuesday, June 27th. This represents a $0.71 dividend on an annualized basis and a dividend yield of 0.22%.

COPYRIGHT VIOLATION NOTICE: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/07/18/ishares-nasdaq-biotechnology-index-fund-nasdaqibb-receiving-somewhat-positive-press-coverage-analysis-shows.html.

About iShares Nasdaq Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Insider Buying and Selling by Quarter for iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply